Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. The company's lead marketed product is ZORYVE, a topical roflumilast cream approved for plaque psoriasis and atopic dermatitis. ZORYVE represents the company's primary revenue stream following its commercialization.

The company maintains a pipeline of dermatology-focused candidates in various stages of development. ARQ-154, a topical foam formulation of roflumilast, is in development for scalp and body psoriasis and seborrheic dermatitis. ARQ-255 and ARQ-252 are JAK1-selective small molecule inhibitors being developed for alopecia areata and hand eczema with vitiligo, respectively. Additionally, ARQ-234, a CD200R fusion protein, is in development for atopic dermatitis.

Based in Westlake Village, California, Arcutis operates as a Delaware-incorporated company with approximately 342 full-time employees. The company is listed on the Nasdaq exchange with a market capitalization of approximately $3.4 billion. Its operations are primarily centered in the United States, focusing on the development and commercialization of topical and systemic dermatological therapies.